Wuhan Diascie Technology Co., Ltd. announced that it has received CNY 24.2863 million in funding from Getein Biotech, Inc.
January 04, 2019
Share
On January 4, 2019, Wuhan Diascie Technology Co., Ltd. closed the transaction. The company has obtained a new business license as issued by the Wuhan Jianghan District Administrative Examination and Approval Bureau. The company now has a registered capital of CNY 24,272,100.
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
GETEIN BIOTECH, INC 
